Aptuit Completes Sale of CTS to Catalent

February 20, 2012

Company News Release

Aptuit announces the completion of the sale of the Clinical Trials Supply business to Catalent Pharma Solutions on February 17, 2012. Timothy C. Tyson, Chairman and CEO of Aptuit, LLC stated that Aptuit will continue to deliver scientific and service excellence to provide integrated capabilities for the early to mid phase drug development markets.

Early to mid-phase services

Aptuit’s early to mid-phase development services include Drug Design and Discovery, Solid State Chemistry, Preclinical Biosciences, API Development and Manufacture, Solid, Oral and Sterile Dosage Formulation, Clinical Sciences, Consulting Services and Aptuit INDiGO&™, our proprietary program for fast track IND submission.

Integrated or stand alone services

Stuart E. Needleman, President, Aptuit Scientific Operations, stressed that Aptuit has a team of scientific professionals in place who speak the client’s language. He explained that they have extensive experience in working with multinational clients and emerging biotechs, and a track record for delivering on time and in full. “We thoroughly understand that business goals and scientific objectives vary greatly from client to client. That’s why we are flexible in offering our clients an Integrated Service Package, consisting of all-inclusive early to mid-phase development services from a single Aptuit location, or stand alone services that are tailored to precisely meet their unique requirements,” said Mr. Needleman.

The global scientific team led by a new CSO

The appointment of a Chief Scientific Officer (CSO) was cited as an example of the company’s focus on scientific excellence. Mr. Needleman said, “The recent appointment of Dr. Jan-Olav Henck is another indication of how Aptuit customers benefit from the leadership and collaboration of some of the industry’s most distinguished and experienced scientific minds.” He further explained that while Aptuit scientists offer drug development expertise across all therapeutic areas, the company includes technical teams of scientific medical specialists who are focused on diseases and therapies that drive the current market, including neuroscience, cardiovascular, oncology and infectious disease.

In discussing Aptuit’s strategically positioned global resources, Needleman cited Aptuit’s facility in Verona, Italy. “While the special strengths of some of our individual global facilities such as Verona are a decided advantage, we are a capability-centric organization: we focus on our client’s needs,” said Mr. Needleman. He added that all sites adhere to the same high quality standards of regulatory compliance.

Related Content:

News